p54/nrb Inhibitors
Chemicals that function as p54/nrb inhibitors encompass a diverse array of compounds, which typically exert their modulatory effects on various aspects of RNA processing and transcription regulation, rather than by directly targeting the p54/nrb protein. The mechanisms by which these inhibitors operate are multifaceted and can include interference with RNA polymerase activity, disruption of the splicing machinery, and alteration of nucleocytoplasmic transport dynamics. Collectively, these inhibitors can modulate the availability of RNA substrates, the assembly and function of RNA processing complexes, and the post-transcriptional modifications of RNA, thereby influencing the cellular activities in which p54/nrb is involved.
The modulation of p54/nrb activity by these inhibitors is an indirect consequence of their primary biochemical actions. For instance, inhibition of transcription elongation affects the supply of RNA transcripts that p54/nrb binds to and processes. Similarly, altering the nucleocytoplasmic distribution of RNA-binding proteins and transcripts can affect the subcellular localization and function of p54/nrb. Inhibition of splicing factor function can change the profile of RNA species in the cell, thereby affecting the regulatory roles played by p54/nrb. Although these compounds are not inhibitors of p54/nrb per se, their effects on transcriptional and post-transcriptional processes can result in the functional modulation of this protein, providing valuable insights into the complex regulatory networks that govern RNA metabolism and gene expression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D intercalates into DNA, inhibiting RNA polymerase and preventing RNA synthesis. This can indirectly influence p54/nrb by limiting the availability of RNA substrates required for its RNA processing functions, leading to modulation of its activity. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
As a potent inhibitor of RNA polymerase II, α-Amanitin effectively blocks mRNA synthesis. p54/nrb's role in RNA splicing and regulation can be indirectly inhibited by reducing mRNA transcript availability. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide covalently modifies the XPB subunit of TFIIH, resulting in the inhibition of transcription. By suppressing overall transcriptional activity, it can reduce p54/nrb's engagement with nascent RNA transcripts, indirectly inhibiting its function in RNA processing. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB acts as an adenosine analog that selectively inhibits RNA polymerase II transcription elongation. This can diminish the transcriptional processes involving p54/nrb, thereby modulating its function indirectly through reduced RNA processing activity. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $107.00 $416.00 $1248.00 | 35 | |
Leptomycin B inhibits nuclear export by binding to exportin 1 (CRM1). p54/nrb's function can be indirectly affected by altering the nucleocytoplasmic transport of proteins and RNA, potentially impacting its role in nuclear retention of transcripts. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits cyclin-dependent kinases (CDKs) and can reduce RNA polymerase II-driven transcription. By lowering the rate of transcription, it can indirectly affect the RNA processing activities of p54/nrb. | ||||||
BMH-21 | 896705-16-1 | sc-507460 | 10 mg | $165.00 | ||
BMH-21 binds to RNA polymerase I, inhibiting ribosomal RNA synthesis. As p54/nrb is involved in RNA-related processes, the reduction of rRNA synthesis can indirectly modulate its function by impacting the cellular rRNA processing machinery. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin is a topoisomerase I inhibitor that prevents the relegation step of DNA replication and transcription. Its use can lead to reduced transcriptional activity, potentially altering p54/nrb’s involvement in RNA processing and transcription regulation by reducing its substrate pool. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin is an adenosine analog that terminates RNA chain elongation. This can indirectly inhibit p54/nrb by curtailing the production of RNA transcripts, thus affecting its RNA processing roles. | ||||||
CX-5461 | 1138549-36-6 | sc-507275 | 5 mg | $245.00 | ||
CX-5461 selectively inhibits RNA polymerase I, thereby specifically reducing rRNA synthesis. This could indirectly modulate p54/nrb's function by affecting the pool of rRNA available for processing, impacting cellular growth and proliferation pathways where p54/nrb may play a role. | ||||||